Cardiovascular effects of current and future anti-obesity drugs

Current Vascular Pharmacology

Volumn 12, Issue 3, 2014, Pages 493-504

  Comerma Steffensen, Simon ^a   Grann, Martin ^a   Andersen, Charlotte U ^b   Rungby, Jørgen ^a,b   Simonsen, Ulf ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiobesity drugs; Brown adipose tissue; Cardiovascular effects; Incretins; SLGT2; TRPV1

Indexed keywords

ACARBOSE; ACETYL COENZYME A CARBOXYLASE; AMFEBUTAMONE PLUS NALTREXONE; AMPHETAMINE; ANTIOBESITY AGENT; BILE ACID; BONE MORPHOGENETIC PROTEIN; CANNABINOID 1 RECEPTOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FENFLURAMINE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIPOPROTEIN LIPASE; LIRAGLUTIDE; LORCASERIN; METFORMIN; NEBIVOLOL; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PRAMLINTIDE; RIMONABANT; SEROTONIN; SIBUTRAMINE; SIRTUIN; TETRAHYDROLIPSTATIN; THYROID HORMONE; TOPIRAMATE; UNCOUPLING PROTEIN 1; VANILLOID RECEPTOR 1;

ANXIETY DISORDER; ARTICLE; BLOOD PRESSURE; BODY MASS; BROWN ADIPOSE TISSUE; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DEFECATION URGENCY; DEPRESSION; DIZZINESS; DRUG EFFECT; FATIGUE; HEADACHE; HEART FAILURE; HEART RATE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; META ANALYSIS (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; QUALITY OF LIFE; STOMACH PAIN; SUICIDAL IDEATION; VALVULAR HEART DISEASE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 84922393826     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666140423223529     Document Type: Article

References (117)

1. [1] CDC statistics, [online] 2010 [cited June 2013]. Available at: www.cdc.gov/datastatistics 2010.
2. [2] Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374-83.
3. [3] Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial-a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273: 219-34.
4. [4] Dorman RB, Serrot FJ, Miller CJ, et al. Case-matched outcomes in bariatric surgery for treatment of type 2 diabetes in the morbidly obese patient. Ann Surg 2012; 255: 287-93.
5. [5] Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-8.
6. [6] James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-17.
7. [7] Hainer V, Hainerova IA. Do we need anti-obesity drugs? Diabetes Metab Res Rev 2012; 28 (Suppl 2): 8-20.
8. [8] Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J 2012; 36: 13-25.
9. [9] Billes SK, Greenway FL. Combination therapy with naltrexone and bupropion for obesity. Expert Opin Pharmacother 2011; 12: 1813-26.
10. [10] Adan RA. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci 2013; 36: 133-40.
11. [11] Charakida M, Finer N. Drug treatment of obesity in cardiovascular disease. Am J Cardiovasc Drugs 2012; 12: 93-104.
12. [12] Drolet B, Simard C, Poirier P. Impact of weight-loss medications on the cardiovascular system: focus on current and future anti- obesity drugs. Am J Cardiovasc Drugs 2007; 7: 273-88.
13. [13] Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther 2011; 90: 40-51.
14. [14] Silvestri C, Di M, V. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs 2012; 21: 1309-22.
15. [15] Yun JW. Possible anti-obesity therapeutics from nature--a review. Phytochemistry 2010; 71: 1625-41.
16. [16] Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009; 8: 308-20.
17. [17] EMA warning. 1997. Anoretics CPMP/100-109/96.
18. [18] Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta- analysis of randomised trials. Lancet 2007; 370: 1706-13.
19. [19] Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo- controlled, phase 3 trial. Lancet 2010; 376: 595-605.
20. [20] Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19: 110-20.
21. [21] Smith SR, Fujioka K, Gupta AK, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab 2013; 15(9): 863-6.
22. [22] [online], [cited June 2013]. Available at: http://www.Clinicaltrials.gov Contrave 2013.
23. [23] Orexigen-CEO interview. http://www.orexigen.com/clinical-trials.html Orexigen-CEO interview 2013.
24. [24] Leniger T, Thone J, Wiemann M. Topiramate modulates pH of hippocampal CA3 neurons by combined effects on carbonic anhydrase and Cl-/. Br J Pharmacol 2004; 142: 831-42.
25. [25] Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013; 23: 725-35.
26. [26] Wilding J, Van GL, Rissanen A, Vercruysse F, Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004; 28: 1399-410.
27. [27] FDA-Qsymia. [online], [cited June 2013], 2013. Available at: FDhttp://www.fda.gov/downloads/Drugs/DrugSafety/UCM312590.pdf 2013.
28. [28] EMA-Qsiva. [online], [cited June 2013], 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002350/smops/Negative/human_smop_000435.jsp&mid=WC0b01ac058001d127.
29. [29] Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-52.
30. [30] Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20: 330-42.
31. [31] Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/ topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297-308.
32. [32] Connolly HM, Crary JL, McGoon MD. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-8.
33. [33] Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-56.
34. [34] Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-77.
35. [35] O'Neil PM, Smith SR, Weissman NJ et al. Randomized placebo- controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012; 20: 1426-1436.
36. [36] Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta- analysis. BMJ 2007; 335: 1194-9.
37. [37] Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
38. [38] Lowell BB, Flier JS. Brown adipose tissue, beta 3-adrenergic receptors, and obesity. Annu Rev Med 1997; 48: 307-16.
39. [39] Stephens M, Ludgate M, Rees DA. Brown fat and obesity: the next big thing? Clin Endocrinol (Oxf) 2011; 74: 661-70.
40. [40] Wehland M, Grosse J, Simonsen U, Infanger M, Bauer J, Grimm D. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease. Curr Vasc Pharmacol 2012; 10: 378-90.
41. [41] Ladage D, Reidenbach C, Rieckeheer E, Graf C, Schwinger RH, Brixius K. Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age. J Cardiovasc Pharmacol 2010; 56: 275-81.
42. [42] Rath G, Balligand JL, Dessy C. Vasodilatory mechanisms of beta receptor blockade. Curr Hypertens Rep 2012; 14: 310-7.
43. [43] Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther 2012; 133: 311-23.
44. [44] Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344: d7771.
45. [45] Astrup A, Rossner S, Van GL, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo- controlled study. Lancet 2009; 374: 1606-16.
46. [46] Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010; 33: 1173-5.
47. [47] Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab 2013; 24: 85-91.
48. [48] Garber AJ. Novel GLP-1 receptor agonists for diabetes. Expert Opin Investig Drugs 2012; 21: 45-57.
49. [49] Mannucci E, Dicembrini I. Incretin-based therapies and cardiovascular risk. Curr Med Res Opin 2012; 28: 715-21.
50. [50] Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide- -the FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362: 774-7.
51. [51] Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012; 61: 1243-9.
52. [52] Wells SA, Jr., Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res 2009; 15: 7119-23.
53. [53] Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012; 153: 1538-47.
54. [54] Israili ZH. Advances in the treatment of type 2 diabetes mellitus. Am J Ther 2011; 18: 117-52.
55. [55] Edelman SV. Optimizing diabetes treatment using an amylin analogue. Diabetes Educ 2008; 34 (Suppl 1): 4S-10S.
56. [56] Hanefeld M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol 2007; 6: 20.
57. [57] Singh S, Bhat J, Wang PH. Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus. Curr Cardiol Rep 2013; 15: 327.
58. [58] Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP- NIDDM randomised trial. Lancet 2002; 359: 2072-7.
59. [59] Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204.
60. [60] Standl E, Schnell O. Alpha-glucosidase inhibitors 2. Diab Vasc Dis Res 2012; 9: 163-9.
61. [61] Cicero AF, Tartagni E, Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci 2012; 8: 907-17.
62. [62] Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35: 731-7.
63. [63] Kabra DG, Kabra UD, Tschöp MH, Hofmann S. Pharmacological Treatment of Obesity. In: Shiromani PJ et al. (Eds.). Sleep Loss and Obesity Intersecting Epidemics. Springer New York, 2012.
64. [64] Gagnon J, Sheppard E, Anini Y. Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabetes Obes Metab 2013; 15: 276-9.
65. [65] Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 2013; 121: 27-31.
66. [66] Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-6.
67. [67] Wulffele MG, Kooy A, de ZD, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004; 256: 1-14.
68. [68] Zhang F, Xiang H, Fan Y, et al. The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine 2013; 44(3): 648-58.
69. [69] Furiex Pharmaceuticals. [online], [cited June 2013], 2013. Available at: http://www.Furiex.com.
70. [70] Villalba JM, Alcain FJ. Sirtuin activators and inhibitors. Biofactors 2012; 38: 349-59.
71. [71] Dominy JE Jr, Lee Y, Gerhart-Hines Z, Puigserver P. Nutrient- dependent regulation of PGC-1alpha's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5. Biochim Biophys Acta 2010; 1804: 1676-83.
72. [72] Alcain FJ, Villalba JM. Sirtuin activators. Expert Opin Ther Pat 2009; 19: 403-14.
73. [73] Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de CR. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 2012; 11: 443-61.
74. [74] Baile CA, Yang JY, Rayalam S, et al. Effect of resveratrol on fat mobilization. Ann N Y Acad Sci 2011; 1215: 40-7.
75. [75] Brasnyo P, Molnar GA, Mohas M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106: 383-9.
76. [76] Ghanim H, Sia CL, Abuaysheh S, et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010; 95: E1-E8.
77. [77] Poulsen MM, Vestergaard PF, Clasen BF, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013; 62: 1186-95.
78. [78] Kassmann M, Harteneck C, Zhu Z, Nurnberg B, Tepel M, Gollasch M. Transient receptor potential vanilloid 1 (TRPV1), TRPV4, and the kidney. Acta Physiol (Oxf) 2013; 207: 546-64.
79. [79] Cui J, Himms-Hagen J. Long-term decrease in body fat and in brown adipose tissue in capsaicin-desensitized rats. Am J Physiol 1992; 262: R568-R573.
80. [80] Melnyk A, Himms-Hagen J. Resistance to aging-associated obesity in capsaicin-desensitized rats one year after treatment. Obes Res 1995; 3: 337-44.
81. [81] Saito M, Yoneshiro T. Capsinoids and related food ingredients activating brown fat thermogenesis and reducing body fat in humans. Curr Opin Lipidol 2013; 24: 71-7.
82. [82] Shinozaki K, Shimizu Y, Shiina T, et al. A neurophysiological evidence of capsaicin-sensitive nerve components innervating interscapular brown adipose tissue. Auton Neurosci 2005; 119: 16-24.
83. [83] Kreutter DK, Orena SJ, Torchia AJ, Contillo LG, Andrews GC, Stevenson RW. Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor. Am J Physiol 1993; 264: E606-E613.
84. [84] Motter AL, Ahern GP. TRPV1-null mice are protected from diet- induced obesity. FEBS Lett 2008; 582: 2257-62.
85. [85] Marshall NJ, Liang L, Bodkin J, et al. A role for TRPV1 in influencing the onset of cardiovascular disease in obesity. Hypertension 2013; 61: 246-52.
86. [86] Zanesco A, Costa SK, Riado SR, et al. Modulation of coronary flow and cardiomyocyte size by sensory fibers. Hypertension 1999; 34: 790-4.
87. [87] Wang L, Wang DH. TRPV1 gene knockout impairs postischemic recovery in isolated perfused heart in mice. Circulation 2005; 112: 3617-23.
88. [88] Ren JY, Song JX, Lu MY, Chen H. Cardioprotection by ischemic postconditioning is lost in isolated perfused heart from diabetic rats: Involvement of transient receptor potential vanilloid 1, calcitonin gene-related peptide and substance P. Regul Pept 2011; 169: 49-57.
89. [89] Harwood HJ, Jr., Petras SF, Shelly LD, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 2003; 278: 37099-111.
90. [90] Waring JF, Yang Y, Healan-Greenberg CH, et al. Gene expression analysis in rats treated with experimental acetyl-coenzyme A carboxylase inhibitors suggests interactions with the peroxisome proliferator-activated receptor alpha pathway. J Pharmacol Exp Ther 2008; 324: 507-16.
91. [91] Krauss S, Zhang CY, Lowell BB. The mitochondrial uncoupling- protein homologues. Nat Rev Mol Cell Biol 2005; 6: 248-261.
92. [92] D'Orazio N, Gemello E, Gammone MA, de GM, Ficoneri C, Riccioni G. Fucoxantin: a treasure from the sea. Mar Drugs 2012; 10: 604-16.
93. [93] Whittle AJ, Carobbio S, Martins L, et al. BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell 2012; 149: 871-85.
94. [94] Pulinilkunnil T, He H, Kong D, et al. Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo. J Biol Chem 2011; 286: 8798-809.
95. [95] Medina-Gomez G. Mitochondria and endocrine function of adipose tissue. Best Pract Res Clin Endocrinol Metab 2012; 26: 791-804.
96. [96] Villarroya F. Irisin, turning up the heat. Cell Metab 2012; 15: 277-8.
97. [97] Pospisilik JA, Schramek D, Schnidar H, et al. Drosophila genome- wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. Cell 2010; 140: 148-60.
98. [98] Matsuura H, Ichiki T, Inoue E, et al. Prolyl Hydroxylase Domain Protein 2 Plays a Critical Role in Diet-induced Obesity and Glucose Intolerance. Circulation 2013; 127: 2078-87.
99. [99] Matsuura H, Ichiki T, Ikeda J, et al. Inhibition of prolyl hydroxylase domain-containing protein downregulates vascular angiotensin II type 1 receptor. Hypertension 2011; 58: 386-93.
100. [100] Wang Z, Schley G, Turkoglu G, et al. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol Dial Transplant 2012; 27: 929-36.
101. [101] Arch JR. Thermogenesis and related metabolic targets in antidiabetic therapy. Handb Exp Pharmacol 2011; (203): 201-55.
102. [102] Holst JJ, McGill MA. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants. Clin Drug Investig 2012; 32: 1-14.
103. [103] Poupon R. Bile acid mimetic-activated TGR5 receptor in metabolic-related liver disorder: the good and the bad. Gastroenterology 2010; 138: 1207-9.
104. [104] Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-77.
105. [105] Torrico F, Cepeda M, Guemo G, et al. Hypoglycaemic effect of Croton cuneatus in streptozotocin-induced diabetic rats. Braz J Pharmacog 2007; 17: 166-9.
106. [106] Silva RM, Oliveira FA, Cunha KM, et al. Cardiovascular effects of trans-dehydrocrotonin, a diterpene from Croton cajucara in rats. Vasc Pharmacol 2005; 43: 11-18.
107. [107] Maciel MA, Pinto AC, Arruda AC, et al. Ethnopharmacology, phytochemistry and pharmacology: a successful combination in the study of Croton cajucara. J Ethnopharmacol 2000; 70: 41-55.
108. [108] Compagnone RS, Chavez K, Mateu E, Orsini G, Arvelo F, Suarez AI. Composition and Cytotoxic Activity of Essential Oils from Croton matourensis and Croton micans from Venezuela. Rec Nat Prod 2010; 4: 101-8.
109. [109] Kang MS, Hirai S, Goto T, et al. Dehydroabietic acid, a diterpene, improves diabetes and hyperlipidemia in obese diabetic KK-Ay mice. Biofactors 2009; 35: 442-8.
110. [110] Lapenda TLS, Morais WA, Lira MCB, Maciel MAM, Santos- Magalhaes NS. Validation of a UV Spectrophotometric Method for Determining trans-dehydrocrotonin in Inclusion Complexes with Hydroxypropyl-beta-Cyclodextrin. Latin Am J Pharm 2012; 31: 97-103.
111. [111] Tam J, Cinar R, Liu J, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab 2012; 16: 167-79.
112. [112] Cluny NL, Vemuri VK, Chambers AP, et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010; 161: 629-42.
113. [113] Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597-604.
114. [114] Kirilly E, Gonda X, Bagdy G. CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol (Oxf) 2012; 205: 41-60.
115. [115] List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-7.
116. [116] Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacol Ther 2013; 139: 51-9.
117. [117] Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 2011; 10: 645-6.